Back

Phospholamban antisense therapy reduces phospholamban aggregation and enhances calcium and contractile kinetics in human phospholamban cardiomyopathy

17 May 2025 (14:15 - 14:30)
Organised by: Logo
Congress Presentation Part of: Young Investigator Award (YIA) Basic Science Gene Therapy, Cell Therapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Frederik Ernst Deiman

University Medical Centre Groningen, Groningen (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3
Doctor V. Quagliariello (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Engineering genetic resilience for cardiometabolic HFpEF: the crucial role of redox homeostasis
Doctor M. Pepin (Stanford, US)
Abstract Slides Video
Presentation thumbnail
A multifactorial porcine model of cardio-metabolic HFpEF highlights miR-483-3p as a promising target therapy
Miss K. Kohlat (German Heart Center Of Charite Berlin, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award (YIA) Basic Science
Video

The Event

Event poster

Heart Failure 2025

17 May 2025 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy
thumbnail
Congress Presentation
Phospholamban antisense treatment attenuates hallmarks of disease in PLN R14del human iPSC derived cardiomyocytes
thumbnail
Congress Presentation
Phosphoproteomics of PLN R14del heart tissue reveals major myocyte degenerate phenotype, and is attenuated by PLN antisense treatment in vitro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources